Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase.

about

Marked regression of myelofibrosis during reduced-dose dasatinib treatment in chronic myelogenous leukemia in accelerated phase.

Item

http://www.wikidata.org/entity/Q53454643

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Marked regression of myelofibr ...... leukemia in accelerated phase.

@en

Marked regression of myelofibr ...... leukemia in accelerated phase.

@nl

type

Item

label

Marked regression of myelofibr ...... leukemia in accelerated phase.

@en

Marked regression of myelofibr ...... leukemia in accelerated phase.

@nl

prefLabel

Marked regression of myelofibr ...... leukemia in accelerated phase.

@en

Marked regression of myelofibr ...... leukemia in accelerated phase.

@nl

P1476

Marked regression of myelofibr ...... leukemia in accelerated phase.

@en

P2093

Elisabeth Huber

http://www.w3.org/2001/XMLSchema#string

Martin Vogelhuber

http://www.w3.org/2001/XMLSchema#string

Roland Christian Schelker

http://www.w3.org/2001/XMLSchema#string

Wolfgang Herr

http://www.w3.org/2001/XMLSchema#string

P2860

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update

Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.

The new landscape of therapy for myelofibrosis.

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.

Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis.

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

P304

219-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1045899

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279303432

http://www.w3.org/2001/XMLSchema#string

P698

26110883

http://www.w3.org/2001/XMLSchema#string